Processa Pharmaceuticals, Inc. focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States.Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the. treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company was incorporated in 2011 and is based in Hanover, Maryland.
